Browsing by author "Corbett, Anna"
Now showing items 21-28 of 28
-
Radiotherapy enhances responses of lung cancer to CTLA-4 blockade.
Wilkins, A; McDonald, F; Harrington, K; Melcher, A (BMC, 2019-03-06)Formenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with palliative radiotherapy in 39 patients with non-small cell ... -
RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy.
Wilkins, A; Hall, E; Lewis, R; Gribble, H; Melcher, A; et al. (ELSEVIER SCIENCE LONDON, 2022-07-01) -
Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology.
Wilkins, A; Melcher, A; Somaiah, N (ELSEVIER SCIENCE LONDON, 2018-10-01) -
The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial.
Brand, DH; Brüningk, SC; Wilkins, A; Naismith, O; Gao, A; et al. (ELSEVIER SCIENCE INC, 2023-02-01)PURPOSE: Moderately hypofractionated external beam intensity modulated radiation therapy (RT) for prostate cancer is now standard-of-care. Normal tissue toxicity responses to fraction size alteration are nonlinear: the ... -
The immunological consequences of radiation-induced DNA damage.
Wilkins, AC; Patin, EC; Harrington, KJ; Melcher, AA (WILEY, 2019-04-01)Historically, our understanding of the cytotoxicity of radiation has centred on tumour cell-autonomous mechanisms of cell death. Here, tumour cell death occurs when a threshold number of radiation-induced non-reparable ... -
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma.
Wilkins, A; Furness, A; Corbett, RW; Bloomfield, A; Porta, N; et al. (NATURE PUBLISHING GROUP, 2015-11-03)BACKGROUND: The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups. It was largely derived using clinical data from patients ... -
TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells.
Anbalagan, S; Ström, C; Downs, JA; Jeggo, PA; McBay, D; et al. (NATURE PORTFOLIO, 2021-03-29)Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient ... -
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Gregucci, F; Spada, S; Barcellos-Hoff, MH; Bhardwaj, N; Chan Wah Hak, C; et al. (TAYLOR & FRANCIS INC, 2023-12-31)Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. ...